


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

RESIGNATION OF NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Director(s)**”) of InSilico Medicine Cayman TopCo (the “**Company**”) announces that Mr. Kan Chen, Ph.D. (“**Mr. Chen**”) has tendered his resignation as a non-executive Director of the Company and a member of the nomination committee of the Board due to changes in his work arrangements and other business commitments that require more of his time and dedication. Such resignation will take effect from July 15, 2026.

The Board further announces that Mr. Long Shi (“**Mr. Shi**”) has tendered his resignation as a non-executive Director of the Company and a member of the remuneration committee of the Board due to changes in his work arrangements and other business commitments that require more of his time and dedication. Such resignation will take effect from July 15, 2026.

The resignations of both Mr. Chen and Mr. Shi are not related to the Company’s business, operations and/or financial performance, and are primarily attributable to the changes in their work arrangements. Each of Mr. Chen and Mr. Shi confirmed that (i) he has no claim against the Company, (ii) he has no disagreement with the Board, and (iii) there are no matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chen and Mr. Shi for their contributions to the Company during their tenure of office.

By order of the Board

InSilico Medicine Cayman TopCo

Mr. Aleksandrs Zavoronkovs, Ph.D.

Chairman, Executive Director, CEO and CBO

Hong Kong, July 15, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive Directors; Mr. Chuen Yan Leung, Ph.D. as non-executive Director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive Directors.